Switch theme
Sign up to access all valuation multiples
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
2023
137
LTM Revenue $30.8M
LTM EBITDA -$35.5M
$32.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Allurion has a last 12-month revenue (LTM) of $30.8M and a last 12-month EBITDA of -$35.5M.
In the most recent fiscal year, Allurion achieved revenue of $32.1M and an EBITDA of -$22.2M.
Allurion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Allurion valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $30.8M | XXX | $32.1M | XXX | XXX | XXX |
| Gross Profit | $21.6M | XXX | $21.5M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | -$35.5M | XXX | -$22.2M | XXX | XXX | XXX |
| EBITDA Margin | -115% | XXX | -69% | XXX | XXX | XXX |
| EBIT | -$35.0M | XXX | -$50.2M | XXX | XXX | XXX |
| EBIT Margin | -114% | XXX | -156% | XXX | XXX | XXX |
| Net Profit | -$16.5M | XXX | -$26.1M | XXX | XXX | XXX |
| Net Margin | -53% | XXX | -81% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $20.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Allurion's stock price is $3.
Allurion has current market cap of $19.8M, and EV of $32.4M.
See Allurion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32.4M | $19.8M | XXX | XXX | XXX | XXX | $-7.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Allurion has market cap of $19.8M and EV of $32.4M.
Allurion's trades at 1.0x EV/Revenue multiple, and -1.5x EV/EBITDA.
Equity research analysts estimate Allurion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Allurion has a P/E ratio of -1.2x.
See valuation multiples for Allurion and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.8M | XXX | $19.8M | XXX | XXX | XXX |
| EV (current) | $32.4M | XXX | $32.4M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | -0.9x | XXX | -1.5x | XXX | XXX | XXX |
| EV/EBIT | -0.9x | XXX | -0.6x | XXX | XXX | XXX |
| EV/Gross Profit | 1.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.2x | XXX | -0.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAllurion's last 12 month revenue growth is 13%
Allurion's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
Allurion's rule of 40 is -116% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Allurion's rule of X is -82% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Allurion and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | -115% | XXX | -69% | XXX | XXX | XXX |
| EBITDA Growth | -60% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -116% | XXX | -56% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -82% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 81% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 223% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Allurion acquired XXX companies to date.
Last acquisition by Allurion was XXXXXXXX, XXXXX XXXXX XXXXXX . Allurion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Allurion founded? | Allurion was founded in 2023. |
| Where is Allurion headquartered? | Allurion is headquartered in United States of America. |
| How many employees does Allurion have? | As of today, Allurion has 137 employees. |
| Who is the CEO of Allurion? | Allurion's CEO is Dr. Shantanu Gaur, M.D.. |
| Is Allurion publicy listed? | Yes, Allurion is a public company listed on NYS. |
| What is the stock symbol of Allurion? | Allurion trades under ALUR ticker. |
| When did Allurion go public? | Allurion went public in 2023. |
| Who are competitors of Allurion? | Similar companies to Allurion include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Allurion? | Allurion's current market cap is $19.8M |
| What is the current revenue of Allurion? | Allurion's last 12 months revenue is $30.8M. |
| What is the current revenue growth of Allurion? | Allurion revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Allurion? | Current revenue multiple of Allurion is 1.1x. |
| Is Allurion profitable? | Yes, Allurion is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Allurion? | Allurion's last 12 months EBITDA is -$35.5M. |
| What is Allurion's EBITDA margin? | Allurion's last 12 months EBITDA margin is -115%. |
| What is the current EV/EBITDA multiple of Allurion? | Current EBITDA multiple of Allurion is -0.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
